GlycoMimetics stockholders approve proposed Crescent Biopharma merger

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jun 05 2025

0mins

Merger Approval: GlycoMimetics' stockholders have approved the merger with Crescent Biopharma and related proposals, including a reverse stock split of 1-for-100.
Trading Changes: The combined company's stock is set to begin trading under the new name "Crescent Biopharma, Inc." on June 16, 2025, on The Nasdaq Capital Market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.